Target Name: ZNF705B
NCBI ID: G100132396
Review Report on ZNF705B Target / Biomarker Content of Review Report on ZNF705B Target / Biomarker
ZNF705B
Other Name(s): putative zinc finger protein 705B | ZNF705B zinc finger protein 705B | zinc finger protein 705B | Putative zinc finger protein 705B | Putative zinc finger protein 705D-like protein LOC100132396 | Z705B_HUMAN

ZNF705B: A Potential Drug Target and Biomarker

The ZNF705B gene, located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric illnesses. ZNF705B is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and has been shown to be involved in the development and progression of several diseases.

The ZNF705B gene was first identified in 2007 as a potential gene for cancer. Researchers found that individuals with certain genetic variations, known as copy number variations, were more likely to develop cervical cancer. The ZNF705B gene was also found to be a common copy number variation in this group of individuals.

In addition to its potential role in cancer, ZNF705B has also been linked to a number of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and can lead to a range of symptoms, including memory loss, movement disorders, and cognitive decline.

ZNF705B has also been shown to be involved in the development and progression of psychiatric illnesses, including depression and anxiety. Studies have found that individuals with major depressive disorder (MDD) and anxiety disorders have lower levels of ZNF705B than those without these disorders. Additionally, individuals with depression have been shown to have reduced levels of ZNF705B in their brain.

Given the potential links between ZNF705B and a number of diseases, researchers are actively exploring its potential as a drug target. One approach being used is to use RNA interference (RNAi) technology to knockdown the expression of ZNF705B in cancer and neurodegenerative disorder cells. This approach has been shown to be effective in reducing the growth and survival of these cells, suggesting that ZNF705B may be a promising target for cancer and neurodegenerative disorders.

Another approach being explored is the use of small interfering RNA (siRNA) technology to target ZNF705B specifically in the brain. This approach has been shown to be effective in reducing the levels of ZNF705B in the brain and may be a more targeted and effective way to explore its potential as a drug target.

In addition to its potential as a drug target, ZNF705B has also been identified as a potential biomarker for several diseases. The ZNF705B gene has been shown to be expressed in a variety of tissues and cells, including brain, spinal cord, and blood cells. This suggests that it may be a useful biomarker for the diagnosis and monitoring of various diseases, including cancer, neurodegenerative disorders, and psychiatric illnesses.

The identification of ZNF705B as a potential drug target and biomarker underscores the importance of further research into its role in the development and progression of diseases. Further studies are needed to fully understand the potential of ZNF705B as a drug target and biomarker, and to determine its safety and effectiveness in clinical trials.

In conclusion, ZNF705B is a non-coding RNA molecule that has been shown to be involved in the regulation of gene expression and the development and progression of several diseases, including cancer, neurodegenerative disorders, and psychiatric illnesses. Further research is needed to fully understand its potential as a drug target and biomarker, and to determine its safety and effectiveness in clinical trials.

Protein Name: Zinc Finger Protein 705B

Functions: May be involved in transcriptional regulation

The "ZNF705B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF705B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF705CP | ZNF705EP | ZNF705G | ZNF706 | ZNF707 | ZNF708 | ZNF709 | ZNF71 | ZNF710 | ZNF711 | ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P